Q1 2025 Earnings Call Transcript September 16, 2024 ImmunoPrecise Antibodies Ltd. misses on earnings expectations. Reported ...

ImmunoPrecise Antibodies (IPA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

ImmunoPrecise Antibodies Ltd. (IPA) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.11 per share a year ago. These ...

ImmunoPrecise Antibodies will report earnings from Q1.Analysts on Wall Street expect ImmunoPrecise Antibodies will release ...

IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA), an artificial intelligence-driven biotherapeutic ...

VICTORIA, British Columbia--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutics company ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

As of 9:52 am GMT+2. Market open. VICTORIA, British Columbia, August 26, 2024--ImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ: IPA), is pleased to announce that it will be attending ...

Good morning, ladies and gentlemen, and thank you for joining us today for ImmunoPrecise Antibodies First Quarter Fiscal Year 2025 Earnings Call. We appreciate your time and interest in our company.

IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA), an artificial intelligence-driven biotherapeutic research and technology company, today reported financial results for ...

Despite a year-over-year revenue decline, IPA shows promising growth in key labs and strategic advancements in AI-driven ...